Vor Bio completes enrollment in Phase 3 UPSTREAM MG trial for telitacicept in generalized myasthenia gravis
VOR•Phase 3 enrollment completed
Vor Bio completed enrollment in its global Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis.
Topline results have not been presented; the 24-week primary endpoint readout remains scheduled for the first half of 2027.
The study aims to show telitacicept can deliver sustained symptom control with a differentiated B-cell modulation approach.
A separate global Phase 3 registrational trial in ocular myasthenia gravis is planned, with first patient dosing expected in the first half of 2027.
